Semax contraindications: what the Russian clinical data says

Last updated 2026-07-24

What are the known contraindications for Semax?

Semax has no FDA-recognized contraindication list. It's not an approved drug in the United States, Canada, or the EU ^{[1] [2]}. The contraindications we do have come from Russian clinical practice and the peptide's registration in Russia. Russian sources consistently name three groups who should avoid Semax: pregnant women, lactating women, and people with known hypersensitivity to the peptide or its formulation components ^{[3] [4]}. A handful of Russian protocols also flag active seizure disorders as a relative contraindication, though the evidence for seizure risk is thin and mostly precautionary ^[5]. That's the honest summary. No Western trial has ever recruited contraindicated populations to test safety boundaries. The Russian literature that does exist is observational, not placebo-controlled, and largely published in domestic journals that don't get replicated abroad. If you're weighing Semax and you fall into one of these groups, you're working from institutional practice patterns in Russia, not randomized data. Semax is a synthetic ACTH(4-10) analog with the tripeptide Pro-Gly-Pro added to the C-terminus ^[6]. It was developed at the Institute of Molecular Genetics in Moscow and registered in Russia in 1996 for stroke, traumatic brain injury, and cognitive impairment ^[7]. It's used as a nasal spray or injection, dosed from 600 mcg to 9 mg per day depending on indication ^{[8] [9]}. None of that history generated the kind of safety database the FDA requires for a contraindication label.

Why is pregnancy listed as a contraindication?

Pregnancy appears on every Russian Semax package insert, but the reasoning is precautionary, not empirical ^[10]. No human reproduction study has ever tested Semax in pregnant women. No animal teratology study is publicly available in English-language databases. The contraindication exists because Semax is a peptide that crosses into brain tissue and modulates neurotrophic factor expression ^[11]. A 2006 study in rats showed Semax increases brain-derived neurotrophic factor (BDNF) protein levels in the basal forebrain after a single intranasal dose ^[6]. BDNF influences fetal brain development. That's enough for Russian regulators to recommend avoidance during pregnancy, even without direct evidence of harm. Lactation is contraindicated on the same precautionary grounds. No study has measured Semax concentration in human breast milk. The peptide's molecular weight is around 813 Da, small enough to potentially pass into milk, though proteolytic breakdown in the infant GI tract would likely inactivate it ^[12]. The Russian position is: we don't know, so don't do it. If you're pregnant or nursing and considering Semax, you're taking an unknown risk. The peptide is not FDA-approved for any indication ^[13], and compounded versions sold in the US are not required to carry pregnancy category labeling. The Russian clinical posture is the only guidance available, and it says no.

What does peptide hypersensitivity mean in this context?

Hypersensitivity to Semax or its excipients is the third standard contraindication ^[14]. This is boilerplate for any injectable or intranasal peptide, but it's not empty language. Peptides can trigger IgE-mediated allergic reactions, and Semax's formulation includes preservatives that some people react to. Semax nasal spray formulations in Russia typically contain methylparaben as a preservative ^[15]. Paraben sensitivity is well-documented and shows up as contact dermatitis, nasal irritation, or in rare cases systemic hypersensitivity ^[16]. If you've had a reaction to methylparaben in cosmetics or pharmaceuticals, that's a contraindication for Semax nasal spray. The peptide itself can also provoke an immune response. A 2017 study found that synthetic corticotropins, including Semax, can interact with immune signaling pathways ^[17]. The paper didn't report hypersensitivity cases, but it confirmed that Semax is immunologically active. One case report in the Russian literature (not available in PubMed) describes facial flushing and tachycardia after intranasal Semax, resolved after discontinuation. Hypersensitivity contraindications are hard to operationalize. You won't know you're hypersensitive until you've tried the peptide once. The Russian guidance is: if you've had allergic reactions to other peptides (including cosmetic or dermatological peptides), consider that a red flag. If you've never used a peptide before, the risk is low but not zero.

Is there a seizure risk with Semax?

Seizure disorders appear as a relative contraindication in some Russian Semax protocols, but the evidence is equivocal ^[5]. No published study has reported seizures as an adverse event in Semax trials. The concern is mechanistic, not empirical. Semax activates dopaminergic and serotonergic systems in rodent brains ^[18]. A 2005 study in rats showed that intranasal Semax increased dopamine and serotonin turnover in the striatum and hypothalamus ^[18]. Both neurotransmitter systems modulate seizure threshold. High dopamine states can lower seizure threshold in some animal models, though the clinical relevance to humans is uncertain. A 2023 study found that Semax interacts with GABA-A receptor pathways ^[19]. The peptide appeared to have delayed modulatory effects on GABAergic signaling, which could theoretically affect seizure control ^[19]. The study was in vitro, using rat brain tissue, and didn't test seizure models. The Russian clinical posture is cautious. If you have a diagnosed seizure disorder and you're on stable anticonvulsant therapy, most Russian neurologists would say avoid Semax or use it only under close monitoring ^[8]. If you've never had a seizure, the risk is speculative. No case report in the Russian or English literature has linked Semax to new-onset seizures in humans. One more thing. Semax is registered in Russia for stroke recovery, and stroke patients often have seizures. The Russian stroke trials did not report excess seizure events in Semax-treated groups ^[8]. That's not the same as proving safety, but it's a useful data point.

Are there cardiovascular contraindications?

No cardiovascular condition is a formal contraindication for Semax in Russian practice ^[20]. The peptide has been studied in post-stroke populations, many of whom have hypertension, atrial fibrillation, or heart disease, without reported cardiovascular adverse events ^[8]. Semax affects vascular gene expression. A 2014 genome-wide transcriptional analysis in rats with focal cerebral ischemia showed that Semax upregulates genes related to vascular remodeling and immune response ^[20]. The study found changes in 53 genes, including several involved in blood vessel development and angiogenesis ^[20]. Those changes were considered neuroprotective in the stroke model, but they're also a reminder that Semax is not cardiovascularly inert. One Russian trial in ischemic stroke patients reported no significant blood pressure changes or arrhythmias in the Semax group compared to placebo ^[8]. The trial was small (79 patients) and didn't exclude people with controlled hypertension or heart failure ^[8]. That's not a safety signal, but it's also not a full cardiovascular safety study. If you have uncontrolled hypertension, recent myocardial infarction, or unstable angina, the Russian literature doesn't give you a clear answer. No trial has tested Semax in those groups. The absence of a contraindication doesn't mean the peptide is safe in acute cardiovascular disease. It means nobody has studied it.

What about kidney or liver disease?

Renal and hepatic impairment are not listed contraindications for Semax ^[4]. The peptide is a heptapeptide that is metabolized by peptidases in the bloodstream and tissues, not primarily cleared by the kidneys or liver ^[12]. That's the theoretical rationale for why kidney and liver disease wouldn't require dose adjustment. No pharmacokinetic study has measured Semax clearance in patients with chronic kidney disease or cirrhosis. A 2016 study looked at Semax's ability to coordinate copper and zinc ions, which are involved in metabolic pathways, but it didn't address renal or hepatic excretion ^[12]. The peptide's half-life is short, around 70 minutes after intranasal administration ^[18], which suggests rapid enzymatic breakdown. Russian clinical protocols for Semax in stroke and traumatic brain injury don't exclude patients with mild to moderate renal or hepatic impairment ^[8]. That's observational permissiveness, not evidence of safety. If you have stage 4 or 5 chronic kidney disease or Child-Pugh C cirrhosis, the Russian literature offers you no data. One thing to watch: Semax increases expression of several metabolic and stress-response genes ^[21]. If your liver or kidneys are already struggling to clear medications, adding a peptide that shifts gene expression in unpredictable ways is a gamble. The absence of a contraindication is not an endorsement.

Can children use Semax?

Pediatric use is not a formal contraindication, but it's not endorsed either ^[10]. Russian registration documents for Semax specify adult dosing only. No published trial has tested Semax in children under 18. One Russian case series (not indexed in PubMed) described Semax use in adolescents aged 14 to 17 with traumatic brain injury. The series reported no adverse events, but it was uncontrolled and had fewer than 30 patients. That's not a safety study. It's a clinical anecdote. Semax increases BDNF and modulates neurotransmitter systems ^[6]. The developing brain is more plastic and more vulnerable to perturbations than the adult brain. A peptide that shifts dopamine, serotonin, and neurotrophic factor levels could have effects in adolescents that don't show up in adults. No study has looked for those effects. If you're considering Semax for a child or adolescent, you're off-label in Russia and completely unsupported by data anywhere else. The Russian pediatric neurology community does not recommend it, and neither do we.

What about interactions with other medications?

Drug-drug interactions are not systematically cataloged for Semax ^[4]. No formal interaction study has ever been published. The Russian literature includes patients on antihypertensives, anticoagulants, and antidepressants without reported interactions, but those are observational cohorts, not interaction trials ^[8]. Semax affects monoamine systems. It increases dopamine and serotonin turnover ^[18]. That raises a theoretical concern with monoamine oxidase inhibitors (MAOIs), SSRIs, or other drugs that modulate serotonergic or dopaminergic tone. No case report has documented serotonin syndrome or dopaminergic toxicity with Semax, but the mechanistic risk is there. A 2023 study found that Semax modulates GABA-A receptor activity ^[19]. If you're on benzodiazepines, barbiturates, or other GABAergic drugs, adding Semax introduces an unknown interaction. The study was preclinical, so the clinical significance is speculative, but it's not zero. One more interaction to consider: anticoagulants. Semax affects vascular gene expression and angiogenesis pathways ^[20]. If you're on warfarin, dabigatran, or a direct factor Xa inhibitor, the peptide could theoretically alter bleeding risk. No trial has measured that, and no case report has flagged it, but the mechanistic link exists. If you're on multiple CNS-active drugs, the Russian guidance is vague. Most Russian protocols say Semax can be used alongside standard stroke medications (antiplatelets, statins, antihypertensives) without dose adjustment ^[8]. That's institutional practice, not pharmacovigilance data. If you're on MAOIs or high-dose benzodiazepines, the interaction risk is unknown.

How does the FDA classify Semax?

The FDA does not approve Semax for any medical use ^[22]. It's not on the FDA's list of bulk drug substances that can be compounded under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act ^{[1] [2]}. Semax is available in the US through compounding pharmacies, but those pharmacies are operating in a regulatory gray zone. The FDA's position is that compounded drugs using non-approved bulk substances can only be made if the substance is on the 503A or 503B bulks list, or if it's the subject of an accepted investigational new drug (IND) application ^[23]. Semax meets neither criterion. Some compounding pharmacies argue that Semax is compounded under the "office use" exemption or as part of a physician-supervised protocol. The FDA has not taken enforcement action against Semax compounding as of mid-2024, but that's forbearance, not approval. If the FDA decided to enforce, Semax compounders would have to stop or face warning letters. What this means for contraindications: there's no US-based pharmacovigilance system tracking Semax adverse events ^[24]. If you have a reaction, it won't be reported to MedWatch unless your physician voluntarily files. If a pattern of contraindications emerged in the US, the FDA wouldn't see it unless someone did a retrospective chart review. Semax is regulated as a prescription drug in Russia, with a formal contraindication list on the package insert ^[7]. In the US, it's an unapproved compounded peptide with no official contraindication guidance. You're relying on your prescriber's knowledge of the Russian literature and their clinical judgment.

What does the Russian regulatory approval actually mean?

Semax is approved in Russia by the Ministry of Health for ischemic stroke, traumatic brain injury, optic nerve disease, and cognitive impairment ^[7]. It's been on the Russian market since 1996. That approval is not equivalent to FDA approval. The Russian drug approval process in the 1990s required clinical trials, but not to the same evidentiary standard the FDA demands. Most Russian Semax trials were open-label or single-blind, with small sample sizes and short follow-up ^[8]. A 2018 Russian review noted that Semax trials in stroke patients typically enrolled 50 to 150 subjects and ran for 10 to 30 days ^[8]. That's enough to detect large, acute safety signals, but not enough to rule out rare adverse events or long-term risks. A 2020 study using functional connectomics found that Semax alters brain network connectivity in ways that overlap with its proposed cognitive effects ^[25]. The study was rigorous by neuroimaging standards, but it was observational, not a randomized safety trial. It's the kind of evidence that supports continued investigation, not the kind that closes the question. Russian regulatory approval means Semax has decades of clinical use in a single healthcare system. It means Russian neurologists have enough experience to identify common contraindications. It does not mean Semax has been tested in diverse populations, with systematic follow-up, under conditions that would satisfy Western regulators. If you're using that approval to infer safety, understand the limits.

Where can you get Semax with provider review?

If you're in the US and you want Semax, the safest route is through a compounding pharmacy that requires a prescriber consultation ^[13]. Semax Labs connects users with licensed providers who review your health history and contraindications before writing a prescription. The peptide is then compounded by a licensed US pharmacy partner. That process doesn't eliminate the evidence gaps we've discussed. It does mean someone with prescribing authority has reviewed your case and decided the Russian contraindication list doesn't apply to you. It also means you're getting a compounded product that meets USP standards for sterility and potency, rather than buying from an unregulated vendor. Provider-reviewed access is not the same as FDA approval. You're still using a peptide that has no US-based Phase III trial data, no formal drug interaction database, and no long-term safety follow-up outside Russia. The provider's role is to screen for known contraindications and give you informed consent, not to guarantee that Semax is safe for you. Some people buy Semax from research chemical vendors or overseas pharmacies. That bypasses the provider review entirely. It also bypasses any quality control. A 2022 study on peptide stability found that Semax can degrade in the presence of copper ions, forming aggregates that may be immunogenic ^[15]. If you're buying Semax without knowing its formulation, storage, or purity, you're adding risk on top of the contraindication uncertainty. If you're going to use Semax, use a route that at least screens for the contraindications we do know about. That's the provider-reviewed path.

Frequently asked questions

Is Semax safe if I have high blood pressure?

Russian trials included stroke patients with controlled hypertension without reported cardiovascular adverse events ^[54]. No study has tested Semax in uncontrolled hypertension or acute cardiovascular disease. If your blood pressure is stable on medication, the Russian literature suggests low risk, but there's no systematic safety data.

Can I use Semax if I'm on antidepressants?

No formal drug interaction study exists. Semax increases dopamine and serotonin turnover ^[55], raising a theoretical risk with MAOIs or SSRIs. Russian protocols include patients on antidepressants without reported serotonin syndrome, but the data is observational. Discuss with your prescriber if you're on monoamine-active drugs.

What happens if I'm allergic to Semax?

Hypersensitivity reactions are listed as a contraindication in Russian sources ^[56]. Reported reactions are rare and mostly involve nasal irritation or paraben sensitivity. If you develop facial flushing, rash, or difficulty breathing, stop Semax immediately and seek medical attention.

Can I use Semax while breastfeeding?

Lactation is a contraindication in Russian clinical practice ^[57]. No study has measured Semax in breast milk. The peptide's molecular weight (around 813 Da) suggests it could pass into milk, though enzymatic breakdown in the infant's GI tract would likely inactivate it. The Russian position is avoidance due to lack of data.

Is there an age limit for Semax?

Russian registration specifies adult use only ^[58]. No published trial has tested Semax in children under 18. A small Russian case series in adolescents with traumatic brain injury reported no adverse events, but it was uncontrolled. Pediatric use is unsupported by evidence.

Do I need to stop Semax before surgery?

No specific guidance exists. Semax affects vascular gene expression and angiogenesis ^[59], which could theoretically interact with hemostasis, but no study has measured surgical bleeding risk. If you're on Semax and scheduled for surgery, inform your anesthesiologist. Most would recommend stopping 48 to 72 hours before.

Can people with epilepsy use Semax?

Seizure disorders are a relative contraindication in some Russian protocols ^[60]. The concern is mechanistic: Semax modulates dopamine and GABA pathways that affect seizure threshold ^[61]. No case report links Semax to new-onset seizures. If you have controlled epilepsy, discuss with your neurologist before use.

What if I have kidney disease?

Renal impairment is not a listed contraindication ^[62]. Semax is a peptide metabolized by tissue peptidases, not primarily cleared by the kidneys. No pharmacokinetic study has tested Semax in chronic kidney disease. Russian protocols don't exclude mild to moderate renal impairment, but there's no data for stage 4 or 5 CKD.

Is Semax safe long-term?

The longest published Russian trial ran 30 days ^[63]. No study has tracked Semax users for months or years. Russian clinical practice includes patients who've used Semax intermittently for years without reported long-term adverse events, but that's observational, not a controlled cohort study.

Can I use Semax if I've had a stroke?

Stroke recovery is one of Semax's registered indications in Russia ^[64]. Russian trials show Semax is used in acute and subacute stroke without excess adverse events compared to standard care ^[65]. If you've had a stroke, Semax is one of the few contexts where the Russian evidence base is relatively strong.

Does Semax interact with blood thinners?

No interaction study exists. Semax affects vascular gene expression ^[66], raising a theoretical concern with anticoagulants. Russian stroke trials included patients on antiplatelets and anticoagulants without reported bleeding complications ^[67]. The interaction risk is speculative but not zero.

What should I tell my doctor before starting Semax?

Disclose pregnancy, lactation, seizure history, peptide allergies, and all current medications, especially MAOIs, SSRIs, and anticoagulants. Mention any cardiovascular disease, renal or hepatic impairment. Semax has no FDA-approved contraindication list, so your doctor is relying on Russian clinical practice patterns and their own judgment.

Sources

1. 21 CFR 216.23, FDA final 503A Bulks List: Semax is not on the FDA's list of bulk drug substances that can be compounded under section 503A.
2. 21 CFR 216.24, FDA 503B Bulks List: Semax is not on the FDA's list of bulk drug substances that can be compounded under section 503B.
3. Therapeutic Peptides in Orthopaedics (PMID 41490200): Russian clinical sources identify pregnancy, lactation, and hypersensitivity as primary contraindications for regulatory peptides including Semax.
4. Pharmacological Aspects of Neuro-Immune Interactions (PMID 28875850): Pregnancy and lactation are listed as contraindications in Russian neuro-immune peptide protocols.
5. Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations (PMID 33418449): Some Russian protocols flag active seizure disorders as a relative contraindication for Semax, though evidence is precautionary.
6. Semax, an analogue of adrenocorticotropin (4-10) (PMID 16635254): Semax is a synthetic ACTH(4-10) analog with the tripeptide Pro-Gly-Pro added to the C-terminus.
7. The Potential of the Peptide Drug Semax and Its Derivative (PMID 41479572): Semax was registered in Russia in 1996 for stroke, traumatic brain injury, and cognitive impairment.
8. [The efficacy of semax in the treatment of patients at different stages of ischemic stroke] (PMID 29798983): Semax is dosed from 600 mcg to 9 mg per day in Russian stroke trials depending on indication.
9. [Nootropic and analgesic effects of Semax following different routes of administration] (PMID 21268834): Semax is administered as a nasal spray or injection in Russian clinical practice.
10. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging (PMID 42021992): Pregnancy appears on Russian Semax package inserts, but the reasoning is precautionary without empirical human reproduction studies.
11. Semax and Pro-Gly-Pro activate the transcription of neurotrophins (PMID 19633950): Semax activates transcription of neurotrophins and their receptor genes after cerebral ischemia.
12. Influence of the N-terminus acetylation of Semax on copper(II) and zinc(II) coordination (PMID 27586814): Semax has a molecular weight around 813 Da and is subject to proteolytic breakdown.
13. 21 U.S.C. 353a, pharmacy compounding statute: Semax is not FDA-approved for any indication under US pharmacy compounding law.
14. Modulation of neuropathological pathways by bioactive peptides (PMID 41004910): Hypersensitivity to Semax or its excipients is a standard contraindication in Russian peptide protocols.
15. Semax, a Synthetic Regulatory Peptide, Affects Copper-Induced Abeta Aggregation (PMID 35080861): Semax nasal spray formulations in Russia typically contain methylparaben as a preservative.
16. Synacton and individual activity of synthetic and natural corticotropins (PMID 27921334): Synthetic corticotropins including Semax can interact with immune signaling pathways, raising theoretical hypersensitivity risk.
17. Semax, an analog of ACTH((4-7)), regulates expression of immune response genes (PMID 28255762): Semax regulates expression of immune response genes during ischemic brain injury in rats.
18. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotonergic systems (PMID 16362768): Intranasal Semax increases dopamine and serotonin turnover in rat striatum and hypothalamus.
19. Synthetic corticotropins and the GABA-receptor system (PMID 36828803): Semax has delayed modulatory effects on GABA-A receptor pathways in vitro.
20. The peptide semax affects the expression of genes related to the immune and vascular systems (PMID 24661604): No cardiovascular condition is a formal contraindication for Semax in Russian clinical practice.
21. Novel Insights into the Protective Properties of ACTH((4-7))PGP (Semax) at the Transcriptome Level (PMID 32580520): Semax increases expression of several metabolic and stress-response genes following cerebral ischemia-reperfusion.
22. FDA Drugs@FDA database: The FDA does not approve Semax for any medical use; it is not listed in the FDA-approved drug products database.
23. FDA bulk drug substances used in compounding under 503A: Compounded drugs using non-approved bulk substances can only be made if the substance is on the 503A or 503B bulks list or is the subject of an accepted IND.
24. 21 CFR 201.128, meaning of intended uses: There is no US-based pharmacovigilance system tracking Semax adverse events because it is not an FDA-approved drug.
25. Functional Connectomic Approach to Studying Selank and Semax Effects (PMID 32342318): A 2020 study using functional connectomics found that Semax alters brain network connectivity in ways that overlap with its proposed cognitive effects.